Table 2.
Trial | No. of patients | Treatment | Follow up (months) | Follow up (method) | Change in LVEF (%) (Treatment vs. control) | p-value |
---|---|---|---|---|---|---|
REVIVAL-2 [62] | 114 | G-CSF | 6 | MRI | 0.5±3.8 vs. 2.0±4.9 | NS |
STEMMI [63] | 78 | G-CSF | 6 | MRI | 8.5 vs. 8 | NS |
G-CSF-STEMI [64] | 44 | G-CSF | 3 | MRI | 6.2±9.0 vs. 5.3±9.8 | NS |
Ellis [65] | 18 | G-CSF | 1 | ECHO | 4.5±11.3/5.2±6.7 vs. 8.0±9.9 | NS |
HEBE III*[66] | EPO | 1,5 | PVR | ongoing | -- |
not double blinded;
LVEF = left ventricular ejection fraction;
G-CSF = granulocyte colonie stimulating factor;
EPO = Erythropoietin;
MRI = magnetic resonance imaging;
ECHO = echocardiography;
PVR = planar radionuclide ventriculography
NS = not significant